Delcath Systems Yönetim
Yönetim kriter kontrolleri 3/4
Delcath Systems CEO'su Gerard Michel, Oct2020 tarihinde atandı, in görev süresi 5.58 yıldır. in toplam yıllık tazminatı $ 5.77M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11% maaş ve 89% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.99% ine doğrudan sahiptir ve bu hisseler $ 3.92M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.9 yıl ve 6 yıldır.
Anahtar bilgiler
Gerard Michel
İcra Kurulu Başkanı
US$5.8m
Toplam tazminat
| CEO maaş yüzdesi | 11.03% |
| CEO görev süresi | 5.6yrs |
| CEO sahipliği | 1.0% |
| Yönetim ortalama görev süresi | 2.9yrs |
| Yönetim Kurulu ortalama görev süresi | 6yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Apr 30
DCTH: 2026 Spend Increase Will Drive Hepatic Cancer Therapy Adoption
Analysts have trimmed their blended price target on Delcath Systems by about $2 to align with recent Street research that lowered the target to $27, citing updated FY26 sales guidance of at least $100m and sharply higher planned R&D and SG&A spending to support HEPZATO commercial and label expansion efforts. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$27 price target as still reflecting upside potential relative to current trading levels, even after trimming expectations.Anlatı Güncellemesi • Apr 16
DCTH: 2026 Spend Increase Will Support Hepatic Cancer Therapy Expansion
Analysts trimmed their price target on Delcath Systems to $27 from $29, citing updated guidance for at least $100M in FY26 sales and a very large projected increase in R&D and SG&A spending to support the HEPZATO label and commercial expansion. Analyst Commentary Recent commentary focuses on how the updated FY26 sales outlook and higher operating spend could affect the risk and reward profile for Delcath Systems, especially around execution on HEPZATO and future label opportunities.
Anlatı Güncellemesi • Apr 02
DCTH: Higher 2026 Spending Will Support Liver Cancer Therapy Expansion
Analysts have trimmed their average price target on Delcath Systems by $2, citing recent FY25 results, updated FY26 sales guidance of at least $100M versus prior consensus of $111M, and expectations for higher R&D and SG&A spending to support HEPZATO growth and label expansion. Analyst Commentary Recent Street commentary on Delcath Systems centers on how near term spending and updated sales guidance could affect the risk and reward profile for shareholders.Anlatı Güncellemesi • Mar 18
DCTH: Higher 2026 Spending Will Support Cancer Therapy Cash Flows And Expansion
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been trimmed by $2 to $27, as analysts factor in the company's FY26 sales guidance of at least $100M, along with sharply higher planned R&D and SG&A spending to support HEPZATO and label expansion. Analyst Commentary Recent research updates on Delcath Systems highlight a mixed reaction to the company’s outlook, with particular attention on FY26 guidance and the spending required to support HEPZATO and label expansion.Anlatı Güncellemesi • Mar 04
DCTH: Higher 2026 Spending Will Support Future Revenue Expansion Potential
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been reduced by $3 to $27. Analysts point to updated FY26 sales guidance of at least $100M and significantly higher projected R&D and SG&A spending to support HEPZATO growth and label expansion as key factors behind the change.Anlatı Güncellemesi • Feb 18
DCTH: Steadier Cancer Therapy Cash Flows Will Support Future Indication Expansion
Analysts have raised their price target on Delcath Systems by $1 to $29, citing preliminary Q4 results that indicate Hepzato is becoming a more stable revenue contributor, with more predictable quarter-to-quarter trends and cash flow that may support expansion plans. Analyst Commentary Analysts highlighting the new US$29 price target point to Hepzato’s role as a steadier revenue source and to cash flow that may help support future expansion plans.Anlatı Güncellemesi • Feb 04
DCTH: Steadier Liver Cancer Therapy Revenues Will Support Future Indication Expansion
Analysts have nudged their price target on Delcath Systems higher to $29 from $28, pointing to Hepzato's role as a steady revenue contributor with more predictable quarter to quarter variability and cash flow that can support expansion of additional indications. Analyst Commentary Even with the higher price target, not all commentary around Delcath Systems leans positive.Anlatı Güncellemesi • Jan 20
DCTH: Steadier Hepatic Therapy Uptake Will Support Future Expansion Plans
Analysts recently lifted their price target on Delcath Systems to $29 from $28, citing Hepzato's role as a steadier and more predictable contributor to revenue and cash flow. They believe this supports potential expansion plans and informs modest adjustments to growth, margin, and future P/E assumptions.Anlatı Güncellemesi • Jan 06
DCTH: CHOPIN Trial Data Will Support Future Uptake Despite Softer Guidance
Analysts have kept their fair value estimate for Delcath Systems steady at $18.00 while adjusting underlying assumptions, citing mixed reactions to softer Q3 and FY2025 revenue guidance alongside supportive CHOPIN trial data and a range of updated price targets from $20 to $30. Analyst Commentary Street research on Delcath Systems has centered on the tension between supportive CHOPIN trial data and softer near term revenue guidance, with several price target revisions reflecting this mixed setup.Anlatı Güncellemesi • Dec 14
DCTH: CHOPIN Data Expected To Drive Stronger Uptake Despite Near-Term Guidance Reset
Analysts have trimmed their fair value estimate for Delcath Systems to $18.00 from $21.00, reflecting lower near term revenue growth assumptions after soft preliminary guidance. This comes despite sustained confidence in Hepzato uptake driven by positive CHOPIN trial data and improving profit margin expectations.Analiz Makalesi • Nov 21
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge
The Delcath Systems, Inc. ( NASDAQ:DCTH ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Nov 06
Delcath: Temporary Headwinds Are No Cause For Concern
Summary Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time. Delcath's valuation is extremely low given the prospect of continued growth and strong margins once growth investments normalize. Read the full article on Seeking AlphaAnaliz Makalesi • Oct 28
The Delcath Systems, Inc. (NASDAQ:DCTH) Analysts Have Been Trimming Their Sales Forecasts
The latest analyst coverage could presage a bad day for Delcath Systems, Inc. ( NASDAQ:DCTH ), with the analysts making...Analiz Makalesi • Aug 09
Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqCM:DCTH 1 Year Share Price vs Fair Value Explore Delcath Systems's Fair Values from the Community and select...Analiz Makalesi • Jul 12
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 29% Share Price Plunge
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 29% in the last month, reversing a fair...Analiz Makalesi • Jun 18
Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analiz Makalesi • May 22
Delcath Systems, Inc.'s (NASDAQ:DCTH) 52% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • May 11
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, Delcath Systems, Inc. ( NASDAQ:DCTH ) came out with a strong set of first-quarter numbers that could...
Yeni Anlatı • May 02
HEPZATO Launch And European Expansion Will Expand Treatment Access
Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.Analiz Makalesi • Mar 11
With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 27% in the last month, reversing a fair...Analiz Makalesi • Jan 18
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders have had their patience rewarded with a 31% share price jump in the...Analiz Makalesi • Dec 19
Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Nov 18
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Summary Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors. Despite promising trends, investors should be cautious of seasonality impacts and the risks associated with upcoming Phase II trials and increased R&D expenses. I take a look at the charts to see if I can identify an opportunity to add to my position. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 01
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Despite an already strong run, Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have been powering on, with a gain of 26...Analiz Makalesi • Sep 10
Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have continued their recent momentum with a 26% gain in the last month...Analiz Makalesi • Aug 27
Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Aug 07
Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Delcath Systems, Inc. ( NASDAQ:DCTH ) filed its quarterly result this time last...Analiz Makalesi • Jan 15
Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$561k |
| Dec 31 2025 | US$6m | US$636k | US$3m |
| Sep 30 2025 | n/a | n/a | US$1m |
| Jun 30 2025 | n/a | n/a | US$2m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$2m | US$561k | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$56m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$3m | US$538k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$34m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$1m | US$521k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$2m | US$475k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$6m | US$113k | -US$24m |
Tazminat ve Piyasa: Gerard 'nin toplam tazminatı ($USD 5.77M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.65M ).
Tazminat ve Kazançlar: Gerard 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Gerard Michel (62 yo)
5.6yrs
Görev süresi
US$5,765,258
Tazminat
Mr. Gerard J. Michel, MS, MBA, is an Independent Director of Beta Bionics, Inc. from March 26, 2025. Mr. Michel serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020....
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$5.77m | 0.99% $ 3.9m | |
| Chief Operating Officer | 2.2yrs | US$2.02m | 0.022% $ 87.8k | |
| Chief Medical Officer | 2.9yrs | US$2.06m | 0.49% $ 1.9m | |
| Chief Financial Officer | 2.9yrs | Veri yok | 0.22% $ 881.9k | |
| General Counsel | 4.3yrs | Veri yok | 0.25% $ 979.6k | |
| Senior Vice President of Clinical Operations & Medical Affairs | 5.3yrs | US$737.50k | Veri yok | |
| Chief Commercial Officer | less than a year | US$1.02m | 0.071% $ 279.2k | |
| Senior Vice President of Interventional Oncology | 1.2yrs | Veri yok | Veri yok |
2.9yrs
Ortalama Görev Süresi
56.5yo
Ortalama Yaş
Deneyimli Yönetim: DCTH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.9 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$5.77m | 0.99% $ 3.9m | |
| Independent Director | 6.3yrs | US$306.22k | 0% $ 0 | |
| Independent Director | 6yrs | US$306.22k | 0.24% $ 941.1k | |
| Independent Chairman | 6.8yrs | US$337.64k | 0.043% $ 171.0k | |
| Independent Director | 6yrs | US$293.72k | 0.15% $ 588.3k | |
| Director | 2yrs | US$301.22k | 0% $ 0 |
6.0yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: DCTH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 11:38 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Delcath Systems, Inc. 12 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| John Newman | Canaccord Genuity |